 | • レポートコード：MRC2305C131 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、258ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界のブランドジェネリック市場規模が2021年に314.55百万ドル、2022年に364.17百万ドルとなり、更に年平均15.95％成長して2027年には764.53百万ドルに達すると予測しています。当市場調査レポートでは、ブランドジェネリックの世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析（商号ジェネリック、付加価値ジェネリック）、用途別分析（抗がん剤、抗感染症、心臓血管、中枢神経系）、流通チャネル別分析（クリニック、病院薬局、薬局）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、当書には、Amneal Pharmaceuticals、Apotex Inc.、AstraZeneca PLC、Aurobindo Pharma Limited、Bausch Health Companies Inc、Cadila Healthcare Limited、Cipla Inc、Dr. Reddy’s Laboratories Ltd.、Endo International PLC、Eris Lifesciences Limited、Eva Pharmaなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のブランドジェネリック市場規模：製品別 - 商号ジェネリックの市場規模 - 付加価値ジェネリックの市場規模 ・世界のブランドジェネリック市場規模：用途別 - 抗がん剤における市場規模 - 抗感染症における市場規模 - 心臓血管における市場規模 - 中枢神経系における市場規模 ・世界のブランドジェネリック市場規模：流通チャネル別 - クリニックチャネルの市場規模 - 病院薬局チャネルの市場規模 - 薬局チャネルの市場規模 ・世界のブランドジェネリック市場規模：地域別 - 南北アメリカのブランドジェネリック市場規模 アメリカのブランドジェネリック市場規模 カナダのブランドジェネリック市場規模 ブラジルのブランドジェネリック市場規模 ... - アジア太平洋のブランドジェネリック市場規模 日本のブランドジェネリック市場規模 中国のブランドジェネリック市場規模 インドのブランドジェネリック市場規模 韓国のブランドジェネリック市場規模 台湾のブランドジェネリック市場規模 ... - ヨーロッパ/中東/アフリカのブランドジェネリック市場規模 イギリスのブランドジェネリック市場規模 ドイツのブランドジェネリック市場規模 フランスのブランドジェネリック市場規模 ロシアのブランドジェネリック市場規模 ... - その他地域のブランドジェネリック市場規模 ・競争状況 ・企業情報 |
The Global Branded Generics Market size was estimated at USD 314.55 million in 2021 and expected to reach USD 364.17 million in 2022, and is projected to grow at a CAGR 15.95% to reach USD 764.53 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Branded Generics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Trade Named Generics and Value-Added.
Based on Application, the market was studied across Anti-Cancer, Anti-Infective, Cardiovascular, and CNS.
Based on Distribution Channel, the market was studied across Clinics, Hospital Pharmacy, and Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Branded Generics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Branded Generics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Branded Generics Market, including Amneal Pharmaceuticals, Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc, Cadila Healthcare Limited, Cipla Inc, Dr. Reddy’s Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Pharmaceuticals, Inc., Mylan N.V., Novartis International AG, Pfizer Inc, Sandoz International GmbH, Sanofi S.A., STADA Arzneimittel AG, Strides Arcolab Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, and Torrent Pharmaceuticals Ltd.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Branded Generics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Branded Generics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Branded Generics Market?
4. What is the competitive strategic window for opportunities in the Global Branded Generics Market?
5. What are the technology trends and regulatory frameworks in the Global Branded Generics Market?
6. What is the market share of the leading vendors in the Global Branded Generics Market?
7. What modes and strategic moves are considered suitable for entering the Global Branded Generics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Off-invoice discounts pharma products
5.1.1.2. Lipid-lowering branded generics with rising obesity
5.1.1.3. Rising incidents and population suffering from chronic diseases and disorders
5.1.2. Restraints
5.1.2.1. Increasing product price pressure
5.1.3. Opportunities
5.1.3.1. Conducive regulatory environment in developing markets
5.1.3.2. R&D investment by pharma companies
5.1.4. Challenges
5.1.4.1. Limited penetration associated with the number of generic drugs
5.2. Cumulative Impact of COVID-19
6. Branded Generics Market, by Product
6.1. Introduction
6.2. Trade Named Generics
6.3. Value-Added
7. Branded Generics Market, by Application
7.1. Introduction
7.2. Anti-Cancer
7.3. Anti-Infective
7.4. Cardiovascular
7.5. CNS
8. Branded Generics Market, by Distribution Channel
8.1. Introduction
8.2. Clinics
8.3. Hospital Pharmacy
8.4. Pharmacy
9. Americas Branded Generics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Branded Generics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Branded Generics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Amneal Pharmaceuticals
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Apotex Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AstraZeneca PLC
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Aurobindo Pharma Limited
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bausch Health Companies Inc
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Cadila Healthcare Limited
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Cipla Inc
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Dr. Reddy’s Laboratories Ltd.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Endo International PLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Eris Lifesciences Limited
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eva Pharma
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Fresenius Kabi
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. GlaxoSmithKline PLC
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Glenmark Pharmaceuticals Limited
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Hetero Drugs Limited
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Lupin Pharmaceuticals, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Mylan N.V.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Novartis International AG
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Pfizer Inc
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Sandoz International GmbH
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Sanofi S.A.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. STADA Arzneimittel AG
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Strides Arcolab Ltd
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Sun Pharmaceutical Industries Ltd
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Teva Pharmaceutical Industries Ltd
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Torrent Pharmaceuticals Ltd
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing